OHSS · intrauterine insemination (IUI) in women with infertility
1 finding from 1 review
Ectopic pregnancy rate per couple · intrauterine insemination (IUI) in women with infertility
Aromatase inhibitors showed no clear difference in ectopic pregnancy rate per couple compared with anti‐oestrogens (low certainty).
1 finding from 1 review
Multiple pregnancy rate · intrauterine insemination (IUI) in women with infertility
Gonadotropins showed no clear difference in multiple pregnancy rate per couple compared with anti‐oestrogens (low certainty).
1 finding from 1 review
Clinical pregnancy rate · intrauterine insemination (IUI) in women with infertility
Gonadotropins probably leads to higher clinical pregnancy rate per couple compared with anti‐oestrogens (moderate certainty).
1 finding from 1 review
Live birth rate per couple · intrauterine insemination (IUI) in women with infertility
It is very uncertain whether aromatase inhibitors with gonadotropins changes live birth rate per couple compared with anti‐oestrogens with gonadotropins (very low certainty).
1 finding from 1 review
Multiple pregnancy rate · intrauterine insemination (IUI) in women with infertility
Aromatase inhibitors with gonadotropins showed no clear difference in multiple pregnancy rate per couple compared with anti‐oestrogens with gonadotropins (low certainty).
1 finding from 1 review
Clinical pregnancy rate · intrauterine insemination (IUI) in women with infertility
It is very uncertain whether aromatase inhibitors with gonadotropins changes clinical pregnancy rate per couple compared with anti‐oestrogens with gonadotropins (very low certainty).
1 finding from 1 review
Miscarriage · intrauterine insemination (IUI) in women with infertility
It is very uncertain whether aromatase inhibitors with gonadotropins changes miscarriage rate per couple compared with anti‐oestrogens with gonadotropins (very low certainty).
1 finding from 1 review
OHSS · intrauterine insemination (IUI) in women with infertility
Aromatase inhibitors with gonadotropins showed no clear difference in OHSS rate per couple compared with anti‐oestrogens with gonadotropins (low certainty).
1 finding from 1 review
Miscarriage · intrauterine insemination (IUI) in women with infertility
Gonadotropins showed no clear difference in miscarriage rate per couple compared with anti‐oestrogens (low certainty).
1 finding from 1 review
OHSS · intrauterine insemination (IUI) in women with infertility
Gonadotropins showed no clear difference in OHSS rate per couple compared with anti‐oestrogens (low certainty).
1 finding from 1 review
Ectopic pregnancy rate per couple · intrauterine insemination (IUI) in women with infertility
Gonadotropins showed no clear difference in ectopic pregnancy rate per couple compared with anti‐oestrogens (low certainty).
1 finding from 1 review
Live birth rate per couple · intrauterine insemination (IUI) in women with infertility
Aromatase inhibitors showed no clear difference in live birth rate per couple compared with anti‐oestrogens (low certainty).
1 finding from 1 review
Multiple pregnancy rate · intrauterine insemination (IUI) in women with infertility
Aromatase inhibitors showed no clear difference in multiple pregnancy rate per couple compared with anti‐oestrogens (low certainty).
1 finding from 1 review
Clinical pregnancy rate · intrauterine insemination (IUI) in women with infertility
Aromatase inhibitors showed no clear difference in clinical pregnancy rate per couple compared with anti‐oestrogens (low certainty).
1 finding from 1 review
Intervention not reported
Breast cancer mortality ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence ‐ AIs · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review